EUVIMEDEUVIMED entdecken
Crossref

Microneedle patch integrated with hydroxyapatite nanoparticles and abemaciclib for treatment of meningioma

Haibo Teng, Qingqing Ren, Cong Feng, Haibo Tao, Yuyi Wang, Hao Shi, Xin Qiao, Zhiyong Liu, Ouying Yan, Hongxu Chen, Xiangdong Zhu, Kai Zhang und 3 weitere

Acta Biomaterialia · 2026-11 · 225 · 645-663

DOI: 10.1016/j.actbio.2026.09.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-11. Verfasst von Haibo Teng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, National Engineering Research Center for Biomaterials, West China Hospital, Sichuan University, Chengdu, 610065, China. Hauptthemen laut MEDLINE: Meningioma, Benzimidazoles, Durapatite, Nanoparticles. Die Arbeit nennt 110 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province, Sichuan Province Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Surgery remains the primary treatment for meningiomas, with radiotherapy used for high-grade tumors, residual disease, and recurrences. However, many high-risk meningiomas progress despite resection or radiotherapy, and effective pharmacological therapies remain lacking. Here, we explored a local microneedle-mediated delivery strategy using gelatin methacryloyl hydrogels (Gel-MA) to co-deliver hydroxyapatite nanoparticles (n-HA) and the selective CDK4/6 inhibitor abemaciclib in meningioma cell-line models. n-HA and abemaciclib were associated with reduced proliferation, increased apoptosis-related signals, and cell-cycle inhibition in the tested models. Exploratory RNA sequencing suggested that n-HA treatment was associated with transcriptional changes related to cellular stress, calcium homeostasis, apoptosis, endocytosis, and immune-related pathways; these findings should be interpreted as hypothesis-generating rather than definitive mechanistic evidence. In an orthotopic xenograft model, local microneedle delivery of n-HA and abemaciclib suppressed tumor progression and was associated with treatment-related histological changes. Overall, this study provides proof-of-concept evidence that a biodegradable microneedle platform may enable local combination therapy for residual, recurrent, or incompletely resectable meningiomas. STATEMENT OF SIGNIFICANCE: Hydroxyapatite nanoparticles (n-HA), a bone-like material, suppress meningioma cell growth while stimulating anti-tumor immune responses, suggesting a therapeutic role beyond structural biomaterials. We further show that n-HA synergizes with abemaciclib to enhance tumor inhibition and immunity. To deliver this combination precisely to the tumor site, we develop GelMA microneedle patches that enable localized and controlled release, reducing reliance on systemic dosing. In animal models, microneedles loaded with n-HA and abemaciclib produce marked anti-tumor effects. Finally, incorporating β-cyclodextrin improves abemaciclib bioavailability, strengthening local therapy. Together, this work introduces an immunoactive biomaterial-drug microneedle strategy with potential for safer, more effective meningioma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaBenzimidazolesDurapatiteNanoparticlesAminopyridinesMeningeal NeoplasmsAnimalsHumansMicroneedle Drug DeliveryCell Line, TumorFemaleMiceMice, NudeXenograft Model Antitumor AssaysCell ProliferationApoptosisHydrogels

Stichwörter der Autor:innen

AbemaciclibApoptosisHydroxyapatite nanoparticles (n-HA)MeningiomasMicroneedles

Substanzen

BenzimidazolesDurapatiteabemaciclibAminopyridinesHydrogels

Autor:innen und Institutionen

  • Department of Neurosurgery, National Engineering Research Center for Biomaterials, West China Hospital, Sichuan University, Chengdu, 610065, China.
  • Department of Emergency Medicine, Laboratory of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, 610065, China.
  • Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, 610065 China.
  • Department of Neurosurgery, National Engineering Research Center for Biomaterials, West China Hospital, Sichuan University, Chengdu, 610065, China. Electronic address: shenwaichx@163.com.
  • Department of Neurosurgery, National Engineering Research Center for Biomaterials, West China Hospital, Sichuan University, Chengdu, 610065, China. Electronic address: hkdlixiangfeng@163.com.
  • Department of Neurosurgery, National Engineering Research Center for Biomaterials, West China Hospital, Sichuan University, Chengdu, 610065, China. Electronic address: xujg@scu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Sichuan Province
  • Sichuan Province Science and Technology Support Program

Zitieren

APA

Teng, H., Ren, Q., Feng, C., Tao, H., Wang, Y., Shi, H., Qiao, X., Liu, Z., Yan, O., Chen, H., Zhu, X., Zhang, K., Li, X., Zhang, X., & Xu, J. (2026). Microneedle patch integrated with hydroxyapatite nanoparticles and abemaciclib for treatment of meningioma. Acta Biomaterialia, 225, 645-663. https://doi.org/10.1016/j.actbio.2026.09.012

Vancouver

Teng H, Ren Q, Feng C, Tao H, Wang Y, Shi H, et al. Microneedle patch integrated with hydroxyapatite nanoparticles and abemaciclib for treatment of meningioma. Acta Biomaterialia. 2026;225:645-663. doi:10.1016/j.actbio.2026.09.012

BibTeX
@article{Teng2026,
  author = {Teng, Haibo and Ren, Qingqing and Feng, Cong and Tao, Haibo and Wang, Yuyi and Shi, Hao and Qiao, Xin and Liu, Zhiyong and Yan, Ouying and Chen, Hongxu and Zhu, Xiangdong and Zhang, Kai and Li, Xiangfeng and Zhang, Xingdong and Xu, Jianguo},
  title = {Microneedle patch integrated with hydroxyapatite nanoparticles and abemaciclib for treatment of meningioma},
  journal = {Acta Biomaterialia},
  year = {2026},
  volume = {225},
  pages = {645--663},
  doi = {10.1016/j.actbio.2026.09.012}
}
Kostenlos starten →